Virtus Fund Advisers LLC Takes Position in Reata Pharmaceuticals Inc (RETA)
Virtus Fund Advisers LLC acquired a new position in shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 13,917 shares of the company’s stock, valued at approximately $394,000.
Other institutional investors also recently made changes to their positions in the company. Nationwide Fund Advisors grew its position in shares of Reata Pharmaceuticals by 38.1% during the second quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock worth $138,000 after buying an additional 1,206 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Reata Pharmaceuticals by 37.4% during the second quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock worth $176,000 after buying an additional 1,521 shares in the last quarter. First Allied Advisory Services Inc. acquired a new position in shares of Reata Pharmaceuticals during the third quarter worth about $203,000. The Manufacturers Life Insurance Company grew its position in shares of Reata Pharmaceuticals by 102.4% during the second quarter. The Manufacturers Life Insurance Company now owns 7,343 shares of the company’s stock worth $233,000 after buying an additional 3,715 shares in the last quarter. Finally, American International Group Inc. grew its position in shares of Reata Pharmaceuticals by 42.5% during the third quarter. American International Group Inc. now owns 7,528 shares of the company’s stock worth $234,000 after buying an additional 2,247 shares in the last quarter. 33.56% of the stock is owned by institutional investors and hedge funds.
Reata Pharmaceuticals Inc (RETA) opened at $24.20 on Friday. The company has a debt-to-equity ratio of -0.15, a current ratio of 3.18 and a quick ratio of 3.18. Reata Pharmaceuticals Inc has a fifty-two week low of $19.48 and a fifty-two week high of $40.88.
A number of brokerages have recently commented on RETA. Zacks Investment Research downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. BidaskClub downgraded Reata Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday. Cowen reaffirmed a “buy” rating on shares of Reata Pharmaceuticals in a report on Thursday, December 14th. Finally, ValuEngine downgraded Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $54.71.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/virtus-fund-advisers-llc-takes-position-in-reata-pharmaceuticals-inc-reta/1890157.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals Inc (NASDAQ:RETA).
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.